Dr Bram Verstockt (Leuven, Belgium) discusses a biopsy study looking at increases NCR+ ILC3 levels in IBD patients on biologic therapy.
IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation…
Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to… read more.
The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab…. read more.
The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber… read more.
As a community IBD professionals are well aware of the need to raise the bar in terms of delivering quality care that maintains tight disease control and anticipates… read more.
Even with access to more potent and sophisticated drugs than ever before, IBD professionals still have a long way to go in optimising treatment and alleviating the long-term… read more.
Perianal fistula is a debilitating complication in CD which affects up to 50% of patients in the course of their disease…
The current research and development pipeline of novel biologic therapies and small molecule drugs promises improved efficacy and safety in the treatment of IBD in the near future…. read more.
ESCP 2017 delegates give their highlights, plus a report on the ESCP/ECCO symposium on ulcerative colitis and a focus on quality of life for patients with perianal Crohn’s disease.
By Maria Dalby (article) and Peter Mas Mollinedo (interviews) The decision to perform a colectomy in patients with ulcerative colitis (UC) should not be made lightly. Such a… read more.
Commentary and insights from Dr Filip Baert, (Roeselare, Belgium) and Usha Chauhan (McMaster University, Canada)